Your Advisors
Michael A. Robinson
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance, and Nexus-9 Network.
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance, and Nexus-9 Network.
Michael'S LATEST HEADLINES
-
This Is the Perfect ETF for 300% Growth… and Wall Street Is Sleeping on It
Cathie Wood of ARK Investment Management is one of today’s savviest fund managers.
But she recently received some flak for making what Michael believes is one of her shrewdest investments yet in a sector likely to grow 300% to hit $82 billion in five years.
And what mainstream Wall Street is turning its nose up at could mean incredible profits for us….
Read more... - This COVID-19 Vaccine Stock Has More Upside Than Pfizer or Moderna
- Silicon Valley's "Top Cop" Tech Stock Could Pay 20% Profits for Starters
- Zillow Stock Is the Key to America’s $1.9 Trillion Housing Boom
- Three Tech Stocks to Load Up on in a Nasdaq Correction
- This Stock's Next 1,100% Profit Wave Starts Now
- The $11 Billion High-Tech Gold Mine Patiently Waiting in the Corner
- This Stock Could Top 116% Gains in 2021
- The Cybersecurity “Ace in the Hole” Company D.C. and Silicon Valley Need Right Now
- Here’s My Favorite Facebook Alternative Right Now